Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q1 2020 · 10-Q
Revenue$828.00K$828.00K+122.6% vs Q1 2019 Net Income-$8.04M-$8.04MN/M vs Q1 2019 EPS Diluted-$2.65-$2.65N/M vs Q1 2019 Operating Income-$7,998,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
Free Cash Flowderived-$8,459,000N/M Margins · derivedOperating margin-965.9%+2188.9 pt vs Q1 2019
Net margin-971.5%+2154.6 pt vs Q1 2019
ended Mar 31, 2020 · filed May 8, 2020 · 38 d after period end